Format

Send to

Choose Destination
Expert Opin Drug Saf. 2016 Aug;15(8):1115-24. doi: 10.1080/14740338.2016.1199682. Epub 2016 Jun 20.

Tiotropium for the treatment of asthma: a drug safety evaluation.

Author information

1
a Department of Pulmonary Medicine and Tuberculosis and Groningen Research Institute for Asthma and COPD , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
2
b Department of Medicine , Firestone Institute for Respiratory Health, McMaster University , Hamilton , ON , Canada.

Abstract

INTRODUCTION:

Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has recently been approved for use in the treatment of asthma in a number of countries, including the EU and the USA, and was incorporated into the 2015 update of the Global Initiative for Asthma treatment guidelines. Here we review safety data from published clinical trials to help inform the use of tiotropium in the treatment of patients with asthma.

AREAS COVERED:

Safety data from recently published clinical trials, which compared tiotropium with placebo or an active control, were reviewed. Trials included children, adolescents, and adults across severities of symptomatic asthma, and assessed tiotropium delivered via the Respimat and HandiHaler devices.

EXPERT OPINION:

Based on the reviewed scientific evidence, tiotropium is a safe and well-tolerated long-acting anticholinergic bronchodilator for use in the treatment of asthma. In the trials assessed, the safety of tiotropium was found to be comparable with that of placebo and alternative therapeutic options, including a doubling in the dose of inhaled corticosteroids and the long-acting β2-agonist salmeterol.

KEYWORDS:

Adverse event; asthma; safety; tiotropium

PMID:
27279414
DOI:
10.1080/14740338.2016.1199682
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center